Latest News

Response Rate Similar Between Low- and Standard-dose Ponatinib

Response Rate Similar Between Low- and Standard-dose Ponatinib

Response with low-dose ponatinib is similar to that of standard-dose ponatinib among patients with refractory chronic myeloid leukemia (CML).

Imatinib Less Beneficial for Patients With CML in Accelerated Phase

Imatinib Less Beneficial for Patients With CML in Accelerated Phase

Patients with chronic myeloid leukemia (CML) in accelerated phase may obtain less clinical benefit with first-line imatinib therapy.

Ibrutinib Linked With Favorable Survival, High Response Rate in CLL

Ibrutinib Linked With Favorable Survival, High Response Rate in CLL

Treatment with ibrutinib may be associated with favorable progression-free and overall survival as well as high overall response rate.

FDA Accepts NDA for Neratinib in HER2+ Early Stage Breast Cancer

FDA Accepts NDA for Neratinib in HER2+ Early Stage Breast Cancer

The FDA accepted a New Drug Application for neratinib for the extended treatment of patients with early HER2-positive breast cancer.

Dalantercept Monotherapy Study Misses Endpoint

Dalantercept Monotherapy Study Misses Endpoint

Treatment with single-agent dalantercept had favorable safety profile in recurrent or metastatic head and neck squamous cell carcinoma.

Bevacizumab Not Recommended in Adjuvant Colorectal Cancer Treatment

Bevacizumab Not Recommended in Adjuvant Colorectal Cancer Treatment

Bevacizumab should not be used with capecitabine as an adjuvant treatment for colorectal cancer.

Addition of Rituximab to Chemo Provides Survival Benefit in Acute Leukemia

Addition of Rituximab to Chemo Provides Survival Benefit in Acute Leukemia

The addition of rituximab to chemotherapy may benefit patients being treated for acute lymphoblastic leukemia (ALL).

Statins Linked to Improved Overall Survival in Multiple Myeloma

Statins Linked to Improved Overall Survival in Multiple Myeloma

In a large cohort of US veterans with multiple myeloma, statin therapy was associated with a decreased risk of all-cause and cancer-specific mortality.

Immunotherapy-related Pneumonitis More Common With Combo Therapy

Immunotherapy-related Pneumonitis More Common With Combo Therapy

Pneumonitis associated with PD-1/PD-L1 monoclonal antibodies is more common when given in combination with anti-CTLA-4 monoclonal antibodies.

Population Disparity in NCI Studies Still Needs Improvement

Population Disparity in NCI Studies Still Needs Improvement

Enrollment disparities in clinical trials improved between 1990 and 2012 for female and elderly patients with lung cancer.

G-CSF Linked With Some Reduction in Neutropenia-related Hospitalization

G-CSF Linked With Some Reduction in Neutropenia-related Hospitalization

Primary G-CSF was associated with low-to-modest benefit in lowering risk for neutropenia-related hospitalization.

CTA Treatment Regimen Chart for Esophageal and EGJ Cancers Updated

CTA Treatment Regimen Chart for Esophageal and EGJ Cancers Updated

CTA has updated its treatment regimen chart for the treatment of esophageal and esophagogastric junction cancers.

Fixed-dose Pembrolizumab Induces Durable Responses in HNSCC

Fixed-dose Pembrolizumab Induces Durable Responses in HNSCC

Study findings support further evaluation of fixed-dose pembrolizumab for patients with recurrent and/or metastatic HNSCC.

Oral REP Regimen Active in Myeloma Refractory to Lenalidomide

Oral REP Regimen Active in Myeloma Refractory to Lenalidomide

Study findings suggest that continuous low-dose cyclophosphamide with lenalidomide and prednisone is a potential multidrug therapeutic strategy for patients with refractory multiple myeloma.

Vasectomy Unlikely to Be a Causal Factor of Aggressive Prostate Cancer

Vasectomy Unlikely to Be a Causal Factor of Aggressive Prostate Cancer

Vasectomy is not linked to either prostate cancer incidence or likelihood of developing aggressive prostate cancer.

Decline in Use of Digital Rectal Examination, PSA Testing

Decline in Use of Digital Rectal Examination, PSA Testing

Following USPSTF recommendations, there has been a decrease in utilization of digital rectal examination and PSA testing,

Recent Decline in Cancer Mortality Among Teenagers, Children

Recent Decline in Cancer Mortality Among Teenagers, Children

There was a decrease in cancer mortality from 1999 to 2014 for children and adolescents aged 1 to 19 years.

Testosterone Appears Safe for Hypogonadal Patients With Prostate Cancer

Testosterone Appears Safe for Hypogonadal Patients With Prostate Cancer

For hypogonadal men with prostate cancer, testosterone treatment seems oncologically safe.

Ricolinostat Appears Safe in Relapsed/Refractory Myeloma

Ricolinostat Appears Safe in Relapsed/Refractory Myeloma

Ricolinostat appears to be safe and well tolerated among patients with relapsed or refractory multiple myeloma.

Massage Therapy May Reduce Chemo-induced Peripheral Neuropathy

Massage Therapy May Reduce Chemo-induced Peripheral Neuropathy

Massage therapy may reduce peripheral neuropathy symptoms among patients receiving neurotoxic chemotherapy.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters